Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

DEPTOR modulates activation responses in CD4+ T cells and enhances immunoregulation following transplantation.

Wedel J, Bruneau S, Liu K, Kong SW, Sage PT, Sabatini DM, Laplante M, Briscoe DM.

Am J Transplant. 2019 Jan;19(1):77-88. doi: 10.1111/ajt.14995. Epub 2018 Aug 17.

PMID:
29969188
2.

DEPTOR at the Nexus of Cancer, Metabolism, and Immunity.

Caron A, Briscoe DM, Richard D, Laplante M.

Physiol Rev. 2018 Jul 1;98(3):1765-1803. doi: 10.1152/physrev.00064.2017. Review.

3.

Study rationale, design, and pretransplantation alloantibody status: A first report of Clinical Trials in Organ Transplantation in Children-04 (CTOTC-04) in pediatric heart transplantation.

Zuckerman WA, Zeevi A, Mason KL, Feingold B, Bentlejewski C, Addonizio LJ, Blume ED, Canter CE, Dipchand AI, Hsu DT, Shaddy RE, Mahle WT, Demetris AJ, Briscoe DM, Mohanakumar T, Ahearn JM, Iklé DN, Armstrong BD, Morrison Y, Diop H, Odim J, Webber SA.

Am J Transplant. 2018 Sep;18(9):2135-2147. doi: 10.1111/ajt.14695. Epub 2018 Mar 23.

4.

Convergent and Divergent Migratory Patterns of Human Neutrophils inside Microfluidic Mazes.

Boneschansker L, Jorgensen J, Ellett F, Briscoe DM, Irimia D.

Sci Rep. 2018 Jan 30;8(1):1887. doi: 10.1038/s41598-018-20060-6.

5.

The intragraft microenvironment as a central determinant of chronic rejection or local immunoregulation/tolerance.

Wedel J, Nakayama H, Kochupurakkal NM, Koch J, Klagsbrun M, Bielenberg DR, Briscoe DM.

Curr Opin Organ Transplant. 2017 Feb;22(1):55-63. doi: 10.1097/MOT.0000000000000373. Review.

6.

Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients.

Daly KP, Stack M, Eisenga MF, Keane JF, Zurakowski D, Blume ED, Briscoe DM.

J Heart Lung Transplant. 2017 Apr;36(4):434-442. doi: 10.1016/j.healun.2016.09.013. Epub 2016 Oct 3.

7.

Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients.

Javaheri A, Molina M, Zamani P, Rodrigues A, Novak E, Chambers S, Stutman P, Maslanek W, Williams M, Lilly SM, Heeger P, Sayegh MH, Chandraker A, Briscoe DM, Daly KP, Starling R, Ikle D, Christie J, Rame JE, Goldberg LR, Billheimer J, Rader DJ.

J Heart Lung Transplant. 2016 Nov;35(11):1295-1302. doi: 10.1016/j.healun.2016.06.022. Epub 2016 Jul 15. Review.

8.

Netrin-1 Augments Chemokinesis in CD4+ T Cells In Vitro and Elicits a Proinflammatory Response In Vivo.

Boneschansker L, Nakayama H, Eisenga M, Wedel J, Klagsbrun M, Irimia D, Briscoe DM.

J Immunol. 2016 Aug 15;197(4):1389-98. doi: 10.4049/jimmunol.1502432. Epub 2016 Jul 18.

9.

Microfluidic mazes to characterize T-cell exploration patterns following activation in vitro.

Jain NG, Wong EA, Aranyosi AJ, Boneschansker L, Markmann JF, Briscoe DM, Irimia D.

Integr Biol (Camb). 2015 Nov;7(11):1423-31. doi: 10.1039/c5ib00146c.

10.

Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study.

Starling RC, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS; CTOT-05 consortium.

Am J Transplant. 2016 Jan;16(1):121-36. doi: 10.1111/ajt.13422. Epub 2015 Aug 10.

11.

Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo.

Nakayama H, Bruneau S, Kochupurakkal N, Coma S, Briscoe DM, Klagsbrun M.

Sci Rep. 2015 Jul 9;5:11789. doi: 10.1038/srep11789.

12.

Translational implications of endothelial cell dysfunction in association with chronic allograft rejection.

Bruneau S, Wedel J, Fakhouri F, Nakayama H, Boneschansker L, Irimia D, Daly KP, Briscoe DM.

Pediatr Nephrol. 2016 Jan;31(1):41-51. doi: 10.1007/s00467-015-3094-6. Epub 2015 Apr 24. Review.

13.

Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection.

Daly KP, Dearling JL, Seto T, Dunning P, Fahey F, Packard AB, Briscoe DM.

Transplantation. 2015 Sep;99(9):e132-9. doi: 10.1097/TP.0000000000000618.

14.

Chronic allograft rejection: a fresh look.

Wedel J, Bruneau S, Kochupurakkal N, Boneschansker L, Briscoe DM.

Curr Opin Organ Transplant. 2015 Feb;20(1):13-20. doi: 10.1097/MOT.0000000000000155. Review.

15.

Microfluidic platform for the quantitative analysis of leukocyte migration signatures.

Boneschansker L, Yan J, Wong E, Briscoe DM, Irimia D.

Nat Commun. 2014 Sep 3;5:4787. doi: 10.1038/ncomms5787.

16.

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction.

Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, Später D, Xu H, Tabebordbar M, Gorbatov R, Sena B, Nahrendorf M, Briscoe DM, Li RA, Wagers AJ, Rossi DJ, Pu WT, Chien KR.

Nat Biotechnol. 2013 Oct;31(10):898-907. doi: 10.1038/nbt.2682. Epub 2013 Sep 8.

17.

DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses.

Bruneau S, Nakayama H, Woda CB, Flynn EA, Briscoe DM.

Blood. 2013 Sep 5;122(10):1833-42. doi: 10.1182/blood-2013-03-488486. Epub 2013 Jul 23.

18.

Differential activation of human T cells to allogeneic endothelial cells, epithelial cells and fibroblasts in vitro.

Samsonov D, Geehan C, Woda CB, Briscoe DM.

Transplant Res. 2012 Apr 24;1(1):4. doi: 10.1186/2047-1440-1-4.

19.

VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients.

Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM, Karumanchi SA, Briscoe DM.

J Heart Lung Transplant. 2013 Jan;32(1):120-8. doi: 10.1016/j.healun.2012.09.030.

20.

Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.

Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O, Briscoe DM, Datta D.

Cytokine Growth Factor Rev. 2013 Feb;24(1):41-9. doi: 10.1016/j.cytogfr.2012.08.007. Epub 2012 Sep 16. Review.

21.

Targeting the intragraft microenvironment and the development of chronic allograft rejection.

Dormond O, Dufour M, Seto T, Bruneau S, Briscoe DM.

Hum Immunol. 2012 Dec;73(12):1261-8. doi: 10.1016/j.humimm.2012.07.334. Epub 2012 Aug 3. Review.

22.

Constitutive activation of the mTOR signaling pathway within the normal glomerulus.

McMahon GM, Datta D, Bruneau S, Kann M, Khalid M, Ho J, Seto T, Kreidberg JA, Stillman IE, Briscoe DM.

Biochem Biophys Res Commun. 2012 Aug 24;425(2):244-9. doi: 10.1016/j.bbrc.2012.07.075. Epub 2012 Jul 22.

23.

Peripherally circulating CD4⁺ FOXP3⁺ CXCR3⁺ T regulatory cells correlate with renal allograft function.

Hoerning A, Köhler S, Jun C, Tebbe B, Fu J, Menke J, Wilde B, Dolff S, Feldkamp T, Briscoe DM, Kribben A, Hoyer PF, Witzke O.

Scand J Immunol. 2012 Sep;76(3):320-8. doi: 10.1111/j.1365-3083.2012.02732.x.

24.

Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation.

Bruneau S, Woda CB, Daly KP, Boneschansker L, Jain NG, Kochupurakkal N, Contreras AG, Seto T, Briscoe DM.

Front Immunol. 2012 Apr 2;3:54. doi: 10.3389/fimmu.2012.00054. eCollection 2012.

25.

TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor.

Bruneau S, Datta D, Flaxenburg JA, Pal S, Briscoe DM.

Biochem Biophys Res Commun. 2012 Mar 2;419(1):66-71. doi: 10.1016/j.bbrc.2012.01.128. Epub 2012 Feb 2.

26.

Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3.

Hoerning A, Koss K, Datta D, Boneschansker L, Jones CN, Wong IY, Irimia D, Calzadilla K, Benitez F, Hoyer PF, Harmon WE, Briscoe DM.

Eur J Immunol. 2011 Aug;41(8):2291-302. doi: 10.1002/eji.201041095. Epub 2011 Jun 24.

27.

Cost-related immunosuppressive medication nonadherence among kidney transplant recipients.

Evans RW, Applegate WH, Briscoe DM, Cohen DJ, Rorick CC, Murphy BT, Madsen JC.

Clin J Am Soc Nephrol. 2010 Dec;5(12):2323-8. doi: 10.2215/CJN.04220510. Epub 2010 Sep 16.

28.

Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Edelbauer M, Datta D, Vos IH, Basu A, Stack MP, Reinders ME, Sho M, Calzadilla K, Ganz P, Briscoe DM.

Blood. 2010 Sep 16;116(11):1980-9. doi: 10.1182/blood-2009-11-252460. Epub 2010 Jun 10.

29.

Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production.

Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K, Pal S, Briscoe DM.

J Immunol. 2010 Jan 15;184(2):545-9. doi: 10.4049/jimmunol.0900397. Epub 2009 Dec 11.

30.

Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.

Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, Pal S.

Cancer Res. 2009 Dec 1;69(23):8902-9. doi: 10.1158/0008-5472.CAN-09-1404. Epub 2009 Nov 10.

31.

mTOR-understanding the clinical effects.

Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, Briscoe DM.

Transplant Proc. 2008 Dec;40(10 Suppl):S9-S12. doi: 10.1016/j.transproceed.2008.10.011. Review.

32.
33.

Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression.

Datta D, Contreras AG, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S.

J Am Soc Nephrol. 2008 Dec;19(12):2437-46. doi: 10.1681/ASN.2008040394. Epub 2008 Oct 2.

34.

Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer.

Basu A, Contreras AG, Datta D, Flynn E, Zeng L, Cohen HT, Briscoe DM, Pal S.

Cancer Res. 2008 Jul 15;68(14):5689-98. doi: 10.1158/0008-5472.CAN-07-6603.

35.

Assessing the vascular effects of early erythropoietin use in pediatric renal transplant recipients.

Briscoe DM, Pal S.

Nat Clin Pract Nephrol. 2008 Mar;4(3):136-7. Epub 2007 Dec 18. No abstract available.

PMID:
18091722
36.

Every allograft needs a silver lining.

Contreras AG, Briscoe DM.

J Clin Invest. 2007 Dec;117(12):3645-8.

37.

Heme oxygenase-1 modulates the expression of the anti-angiogenic chemokine CXCL-10 in renal tubular epithelial cells.

Datta D, Dormond O, Basu A, Briscoe DM, Pal S.

Am J Physiol Renal Physiol. 2007 Oct;293(4):F1222-30. Epub 2007 Jul 25.

38.

Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection.

Haskova Z, Izawa A, Contreras AG, Flynn E, Boulday G, Briscoe DM.

Transplantation. 2007 Jun 27;83(12):1595-601.

PMID:
17589343
39.

The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells.

Dormond O, Madsen JC, Briscoe DM.

J Biol Chem. 2007 Aug 10;282(32):23679-86. Epub 2007 Jun 6.

40.

Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.

Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S.

Cancer Res. 2006 Oct 1;66(19):9509-18.

41.

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE.

Cancer Cell. 2006 Aug;10(2):159-70.

43.

Angiogenesis and endothelial cell repair in renal disease and allograft rejection.

Reinders ME, Rabelink TJ, Briscoe DM.

J Am Soc Nephrol. 2006 Apr;17(4):932-42. Epub 2006 Feb 15. Review.

44.

Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury.

Tsuchihashi S, Ke B, Kaldas F, Flynn E, Busuttil RW, Briscoe DM, Kupiec-Weglinski JW.

Am J Pathol. 2006 Feb;168(2):695-705.

45.

Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo.

Sho M, Akashi S, Kanehiro H, Hamada K, Kashizuka H, Ikeda N, Nomi T, Kuzumoto Y, Tsurui Y, Yoshiji H, Wu Y, Hicklin DJ, Briscoe DM, Nakajima Y.

Transplantation. 2005 Sep 27;80(6):717-22.

PMID:
16210956
46.

CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells.

Laxmanan S, Datta D, Geehan C, Briscoe DM, Pal S.

J Am Soc Nephrol. 2005 Sep;16(9):2714-23. Epub 2005 Jul 20.

47.

Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.

Laxmanan S, Robertson SW, Wang E, Lau JS, Briscoe DM, Mukhopadhyay D.

Biochem Biophys Res Commun. 2005 Aug 19;334(1):193-198. doi: 10.1016/j.bbrc.2005.06.065.

48.

TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy.

Denton MD, Magee C, Melter M, Dharnidharka VR, Sayegh MH, Briscoe DM.

Transplantation. 2004 Oct 27;78(8):1218-21.

PMID:
15502723
50.

CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island.

Lapchak PH, Melter M, Pal S, Flaxenburg JA, Geehan C, Frank MH, Mukhopadhyay D, Briscoe DM.

Am J Physiol Renal Physiol. 2004 Sep;287(3):F512-20. Epub 2004 May 12.

Supplemental Content

Loading ...
Support Center